$ZLAB

Edmondson Frazor Titus III sold $72K of ZLAB

Edmondson Frazor Titus III (Chief Legal Officer) sold 4,103 shares of Zai Lab Ltd (ZLAB) at $17.46 on 2026-06-26.

Original reporting
SEC EDGAR · Edmondson Frazor Titus III
Published Jun 29, 2026, 8:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ZLAB
Neutral
medium confidence
Mentioned
$ZLAB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

The newest concrete fact is the specific open-market sale (4,103 shares at $17.4610) and the post-sale holdings (30,346 shares).

02

Market read

Traders may note the insider sale for sentiment, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales often occur for non-informational reasons; without context on prior sales, option exercises, or compensation structure, directional inference is weak.

Relevance 3/10Novelty 4/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The filing is an SEC Form 4 insider transaction for Zai Lab Ltd, reported by the Chief Legal Officer.

Company-level read

Ticker impact

$ZLABNeutralMedium confidence
Context

Zai Lab insider Form 4 shows Chief Legal Officer Edmondson Frazor Titus III sold 4,103 shares at $17.4610 on 2026-06-26.

Expected impact

Likely limited near-term impact; may slightly affect sentiment but lacks fundamental catalyst.

Evidence & confidence

Form 4 is primary-source and time-stamped, but the disclosure is an insider sale without accompanying company news (no guidance, trial, deal, or enforcement action).

Market effects

Minimal—single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Absence of a disclosed 10b5-1 plan could be interpreted as less “scheduled,” but the transaction is still small and may reflect diversification or tax planning rather than bearish fundamentals.

Key entities

  • Zai Lab Ltd

    Subject of the Form 4 insider transaction; Chief Legal Officer reported an open-market sale.

  • Edmondson Frazor Titus III

    Chief Legal Officer who sold 4,103 shares of Zai Lab on 2026-06-26.

Related articles

$ZLABMed

Zai Lab Q2 Earnings Call Highlights

Zai Lab (NASDAQ:ZLAB) said it plans to seek China NRDL inclusion for VYVGART HYTRULO and shift the VYVGART franchise from IV to subcutaneous. Management flagged timing effects on second-half revenue, aims to stabilize revenue before stronger 2027 growth, and reported $717.5M cash. It outlined zoci ADC Phase III plans and pipeline updates.

$ZLABMed

Zai Lab Ltd (ZLAB): Results of Operations and Financial Condition

Zai Lab Ltd (ZLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zlab-202686x8kex991.htm EX-99.1 Document Exhibit 99.1 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates – The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with signifi